<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7677582</article-id><article-id pub-id-type="pmcid-ver">PMC7677582.1</article-id><article-id pub-id-type="pmcaid">7677582</article-id><article-id pub-id-type="pmcaiid">7677582</article-id><article-id pub-id-type="pmid">33240278</article-id><article-id pub-id-type="doi">10.3389/fimmu.2020.589833</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Adjuvants for Coronavirus Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liang</surname><given-names initials="Z">Zhihui</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1128195"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="H">Haoru</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xin</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1093479"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jing</surname><given-names initials="B">Bo</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1128495"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Z">Zifan</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1128270"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xia</surname><given-names initials="X">Xinyu</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1128223"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="H">Hongwu</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/364134"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="Y">Yun</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/307409"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Weiting</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="L">Li</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="author-notes" rid="fn003">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="H">Hao</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="B">Bingbing</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1047681"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>State Key Laboratory of Fine Chemicals, Dalian University of Technology</institution>, <addr-line>Dalian</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>School of Chemical Engineering, Dalian University of Technology</institution>, <addr-line>Dalian</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>NCPC Genetech Biotechnology Co., Ltd.</institution>, <addr-line>Shijiazhuang</addr-line>, <country>China</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Basic Research Department, Shanghai Zerun Biotechnology Co., Ltd.</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Katie Ewer, University of Oxford, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Anke Huckriede, University Medical Center Groningen, Netherlands; Andrew Ishizuka, National Institutes of Health (NIH), United States; Tamiru Alkie, Wilfrid Laurier University, Canada</p></fn><corresp id="fn001">*Correspondence: Bingbing Sun, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:bingbingsun@dlut.edu.cn">bingbingsun@dlut.edu.cn</email>; Hao Zeng, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:zeng1109@163.com">zeng1109@163.com</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn><fn fn-type="present-address" id="fn003"><p>&#8224;Present Address: Li Shi, Immune Path Biotechnology Co., Ltd., Suzhou, China</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">351098</issue-id><elocation-id>589833</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>11</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>24</day><month>11</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-29 12:25:13.173"><day>29</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020 Liang, Zhu, Wang, Jing, Li, Xia, Sun, Yang, Zhang, Shi, Zeng and Sun</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Liang, Zhu, Wang, Jing, Li, Xia, Sun, Yang, Zhang, Shi, Zeng and Sun</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-11-589833.pdf"/><abstract><p>Vaccine development utilizing various platforms is one of the strategies that has been proposed to address the coronavirus disease 2019 (COVID-19) pandemic. Adjuvants are critical components of both subunit and certain inactivated vaccines because they induce specific immune responses that are more robust and long-lasting. A review of the history of coronavirus vaccine development demonstrates that only a few adjuvants, including aluminum salts, emulsions, and TLR agonists, have been formulated for the severe acute respiratory syndrome-associated coronavirus (SARS-CoV), Middle East respiratory syndrome-related coronavirus (MERS-CoV), and currently the SARS-CoV-2 vaccines in experimental and pre-clinical studies. However, there is still a lack of evidence regarding the effects of the adjuvants tested in coronavirus vaccines. This paper presents an overview of adjuvants that have been formulated in reported coronavirus vaccine studies, which should assist with the design and selection of adjuvants with optimal efficacy and safety profiles for COVID-19 vaccines.</p></abstract><kwd-group><kwd>coronavirus disease 2019</kwd><kwd>SARS-CoV-2</kwd><kwd>adjuvant</kwd><kwd>coronavirus vaccine</kwd><kwd>aluminum salt</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content></funding-source><award-id rid="cn001">31870919</award-id></award-group><award-group><funding-source id="cn002">Natural Science Foundation of Liaoning Province<named-content content-type="fundref-id">10.13039/501100005047</named-content></funding-source><award-id rid="cn002">20180550597</award-id></award-group><award-group><funding-source id="cn003">Fundamental Research Funds for the Central Universities<named-content content-type="fundref-id">10.13039/501100012226</named-content></funding-source><award-id rid="cn003">DUT19TD12</award-id></award-group></funding-group><counts><fig-count count="0"/><table-count count="3"/><equation-count count="0"/><ref-count count="84"/><page-count count="10"/><word-count count="5972"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Coronaviruses (CoVs) are single-stranded RNA viruses characterized by club-like spikes that can potentially cause severe respiratory disease in humans (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). The outbreak of severe acute respiratory syndrome (SARS) caused by the SARS-CoV resulted in more than 8000 confirmed infections, with an overall case fatality rate of 10% in 2002 (<xref rid="B3" ref-type="bibr">3</xref>). The Middle East respiratory syndrome (MERS)-CoV continues to cause deaths with increasing geographical distribution and a 34.4% case fatality rate, according to the World Health Organization (WHO) (<xref rid="B4" ref-type="bibr">4</xref>). Most recently, the coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has spread globally, with over 33 million confirmed cases as of October 2020 (<xref rid="B5" ref-type="bibr">5</xref>). Considering the challenges to global health systems and the far-reaching consequences on the world economy, there is an urgent need to develop effective and safe vaccines that can be quickly deployed on a global scale (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B6" ref-type="bibr">6</xref>).</p><p>Vaccine candidates are currently under development using different platforms, such as inactivated vaccines, recombinant protein vaccines, live-attenuated vaccines, viral vector (adenovirus) vaccines, DNA vaccines, and mRNA vaccines (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Adenovirus-vector could induce potent immunological responses due to the presence of viral proteins and stimulation of innate immunity sensors, <italic toggle="yes">e.g.</italic>, toll-like receptors (<xref rid="B8" ref-type="bibr">8</xref>). Nucleic-acid vaccines, <italic toggle="yes">e.g.</italic>, DNA and mRNA vaccines, encode the virus&#8217;s spike protein, intrinsically could engage innate immunity that instructs induction of immune protection (<xref rid="B9" ref-type="bibr">9</xref>). However, these platforms haven&#8217;t been used in licensed human vaccines before. In other platforms, subunit or inactivated antigens were used, but these antigens lack the immunological profiles that mediate the enhanced adaptive immunity. Thus, in these CoV vaccines, they require the addition of adjuvants for directing the types and magnitude of immune responses (<xref rid="B10" ref-type="bibr">10</xref>). In previously reported exploratory and pre-clinical CoV vaccine studies, adjuvants such as aluminum salts, emulsions, and toll-like receptor (TLR) agonists, have been used in vaccine formulations for studies with various animal models (<xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>). The adjuvants AS03, MF59, and CpG 1018 have already been used in licensed vaccines (<xref rid="B28" ref-type="bibr">28</xref>) and have been committed by GlaxoSmithKline, Seqirus, and Dynavax to be available for COVID-19 vaccine development (<xref rid="B29" ref-type="bibr">29</xref>). When combined with subunit and specific inactivated antigens (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>), adjuvants with various characteristics elicit distinctive immunological profiles with regard to the direction, duration, and strength of immune responses. Thus far, there are at least 40 candidate vaccines in clinical trials and 149 vaccines in preclinical evaluation, of which 67 subunit and 15 inactivated COVID-19 vaccines have being developed (<xref rid="B32" ref-type="bibr">32</xref>). Among these adjuvants, alum have been formulated with S protein or RBD to induce neutralizing antibody production (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>), which has suggested to be associated with protection against SARS-CoV-2 (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B24" ref-type="bibr">24</xref>). However, alum lacks the capability to promote the activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses, which has been demonstrated to coordinate with the antibody responses to provide protective immunity against the SARS-CoV-2 (<xref rid="B33" ref-type="bibr">33</xref>). Other adjuvants, <italic toggle="yes">e.g.</italic>, emulsion adjuvants and TLR agonists, which have been shown to induce both humoral and cellular immune responses could be more favorable. However, no phase III clinical trial results of COVID-19 vaccines are published so far, thus, there is no direct evidence to indicate which type of immune response induced by vaccine plays a more critical protective role in SARS-CoV-2 infection. Knowing these uncertainties, an overview of previous CoV vaccine studies using different adjuvants would be indispensable for the design and development of a COVID-19 vaccine.</p><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Alum based adjuvants used in the coronavirus vaccine formulations under exploratory and pre-clinical investigations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="2" align="left" colspan="1">Adjuvant Type</th><th valign="top" rowspan="2" align="center" colspan="1">Platform</th><th valign="top" rowspan="2" align="center" colspan="1">Adjuvant</th><th valign="top" rowspan="2" align="center" colspan="1">Antigen</th><th valign="top" rowspan="2" align="center" colspan="1">Antigen Dose</th><th valign="top" colspan="8" align="center" rowspan="1">Immunological response</th><th valign="top" rowspan="2" align="center" colspan="1">Route</th><th valign="top" rowspan="2" align="center" colspan="1">Immunization Schedule</th><th valign="top" rowspan="2" align="center" colspan="1">Safety</th><th valign="top" rowspan="2" align="center" colspan="1">Animal model</th><th valign="top" rowspan="2" align="center" colspan="1">Ref.</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Nab</th><th valign="top" align="center" rowspan="1" colspan="1">IgG<sub>1</sub>
</th><th valign="top" align="center" rowspan="1" colspan="1">IgG<sub>2a</sub>
</th><th valign="top" align="center" rowspan="1" colspan="1">IgA</th><th valign="top" align="center" rowspan="1" colspan="1">Th1 cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">Th2 cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">Th17 Cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">CD8<sup>+</sup> T cell response</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Alum based adjuvants</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">Doubly inactivated (formalin and UV) whole SARS virus</td><td valign="top" align="left" rowspan="1" colspan="1">0.125/0.25/0.5/1 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Pulmonary immunopathology</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c or C57BL/6 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B11" ref-type="bibr">11</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">Purified beta propiolactone inactivated whole SARS virus</td><td valign="top" align="left" rowspan="1" colspan="1">2 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c or C57BL/6 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B11" ref-type="bibr">11</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide gel</td><td valign="top" align="left" rowspan="1" colspan="1">UV-inactivated purified SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B12" ref-type="bibr">12</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV (formaldehyde and U.V. inactivation)</td><td valign="top" align="left" rowspan="1" colspan="1">0.3~1 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">CD1<break/>mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B13" ref-type="bibr">13</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Alum</td><td valign="top" align="left" rowspan="1" colspan="1">Double-inactivated SARS-CoV (DIV)</td><td valign="top" align="left" rowspan="1" colspan="1">0.2 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">Footpad injection</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Lung immunopathology</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c AnNHsd mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B14" ref-type="bibr">14</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Mice/Rats:1.5/3/6 &#956;g; Monkeys:1.5/6 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m./i.p.</td><td valign="top" align="center" rowspan="1" colspan="1">Mice/Rats:2;<break/>Monkeys:3</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice; Wistar rats; Rhesus macaques</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B15" ref-type="bibr">15</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">2/4/8<break/>(&#956;g/dose)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.p./i.m</td><td valign="top" align="center" rowspan="1" colspan="1">1/2/3</td><td valign="top" align="center" rowspan="1" colspan="1">No acute toxicity/No Systemic anaphylax/No long-term toxicity</td><td valign="top" align="left" rowspan="1" colspan="1">Rats; Mice guinea pigs; Rabbits, Cynomol-gus monkeys; Rhesus macaques</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B16" ref-type="bibr">16</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Alhydrogel</td><td valign="top" align="left" rowspan="1" colspan="1">SARS S protein</td><td valign="top" align="left" rowspan="1" colspan="1">3 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B17" ref-type="bibr">17</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Alhydrogel</td><td valign="top" align="left" rowspan="1" colspan="1">MERS S protein</td><td valign="top" align="left" rowspan="1" colspan="1">1/3/10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B17" ref-type="bibr">17</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S rRBD Protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B18" ref-type="bibr">18</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Alhydrogel</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S318&#8211;510 fragment</td><td valign="top" align="left" rowspan="1" colspan="1">8 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">129S6/SvEv mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B19" ref-type="bibr">19</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Alhydrogel</td><td valign="top" align="left" rowspan="1" colspan="1">Ectodomain of SARS-CoV S glycoprotein (&#916;TMS)</td><td valign="top" align="left" rowspan="1" colspan="1">1//5 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">CD1 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B20" ref-type="bibr">20</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">S glycoprotein of SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">0.25/0.5/1/2 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c or C57BL/6 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B11" ref-type="bibr">11</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV rRBD protein S367-606</td><td valign="top" align="left" rowspan="1" colspan="1">100/50 &#956;g (primed)+50/25 &#956;g (boosted)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">Monkeys</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B21" ref-type="bibr">21</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum phosphate</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S1 protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B22" ref-type="bibr">22</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Imject&#8482; Alum</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV RBD-dimer</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B23" ref-type="bibr">23</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide gel</td><td valign="top" align="left" rowspan="1" colspan="1">RBD of SARS-CoV-2 spike protein</td><td valign="top" align="left" rowspan="1" colspan="1">0.1-20 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m</td><td valign="top" align="center" rowspan="1" colspan="1">1/2/3</td><td valign="top" align="center" rowspan="1" colspan="1">Safe</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c and C57BL/6mice; Rabbits;Non-human primates (Macaca mulatta)</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B24" ref-type="bibr">24</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">VLP vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Aluminum hydroxide</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV S glycoprotein and E, M, and N proteins</td><td valign="top" align="left" rowspan="1" colspan="1">2 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c or C57BL/6 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B11" ref-type="bibr">11</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>Annotation:</p></fn><fn><p>
<bold>S protein</bold> is the spike glycoprotein of coronavirus and a main target for neutralizing antibodies (<xref rid="B25" ref-type="bibr">25</xref>);</p></fn><fn><p>
<bold>RBD</bold> is the receptor-binding domain (RBD) of S protein, which could directly interact with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells (<xref rid="B25" ref-type="bibr">25</xref>);</p></fn><fn><p>
<bold>N protein</bold> is the highly conserved nucleocapsid protein of coronavirus and regulates RNA replication and transcription (<xref rid="B26" ref-type="bibr">26</xref>);</p></fn><fn><p>
<bold>M protein</bold> (membrane protein) is the most abundant protein on the coronavirus surface and mediates virus assembly (<xref rid="B25" ref-type="bibr">25</xref>);</p></fn><fn><p>
<bold>E protein</bold> (envelope protein) is an integral membrane protein and plays a pivotal role in virus envelope formation (<xref rid="B27" ref-type="bibr">27</xref>).</p></fn><fn><p>
<bold>Nab</bold> represents the neutralizing antibodies, and N/A means not available.</p></fn></table-wrap-foot></table-wrap><p>The SARS-CoV-2 is a novel strain of the coronavirus, and very little is known about its epidemiology and pathogenesis. Therefore, extreme cautions should be taken when considering vaccine formulations that can achieve the desired efficacy and safety profiles. The selection of adjuvants should consider the magnitude, affinity, isotype, and durability of antibodies that are critical for coronavirus vaccine developments (<xref rid="B34" ref-type="bibr">34</xref>). It should be noted that low antibody production may lead to antibody-dependent enhancement (ADE) manifested by severe liver damage and enhanced infection (<xref rid="B35" ref-type="bibr">35</xref>), while high affinity neutralizing antibodies could help to avoid ADE. Additionally, the proper application of adjuvants also depends on the choice of antigens. The full-length S protein is more likely to trigger ADE due to mild antibody production (<xref rid="B36" ref-type="bibr">36</xref>). In comparison, the N protein is generally highly conserved, and it is associated with the ability to induce cytotoxic T lymphocytes (CTL). However, N protein could potentiate pro-inflammatory cytokine production and lead to severe lung pathology (<xref rid="B37" ref-type="bibr">37</xref>). In addition, previous study on respiratory syncytial virus (RSV) vaccine also indicated that immunization with whole inactivated virus could lead to vaccine-associated enhanced respiratory disease (VAERD), manifested by allergic inflammation and Th2 type immune responses (<xref rid="B38" ref-type="bibr">38</xref>). Altogether, these studies suggest that vaccines formulated with various antigen isotypes may require proper adjuvant selection to achieve the desired immune protection. In this paper, we reviewed adjuvants that have already been incorporated in the coronavirus vaccines under exploratory and pre-clinical investigations. By reviewing the vaccine formulations and the types of immune responses that were induced, we provide information that will enable proper adjuvant selection for COVID-19 vaccines to facilitate rapid vaccine delivery.</p></sec><sec id="s2"><title>Aluminum Salt-Based Adjuvants</title><p>Aluminum salt-based adjuvants (alum) were the first adjuvants used in licensed human vaccines. They are still the most widely used because of their wide-spectrum ability to strengthen immune responses and their excellent track record of safety (<xref rid="B39" ref-type="bibr">39</xref>&#8211;<xref rid="B41" ref-type="bibr">41</xref>). In limited coronavirus vaccine studies, it has been suggested that neutralizing antibody against the spike protein might be mechanistically correlated with immune protection (<xref rid="B42" ref-type="bibr">42</xref>). When alum was formulated with S protein or receptor-binding&#160;domain&#160;(RBD), it significantly enhanced humoral immune responses. This was demonstrated by higher titers of serum IgG<sub>1</sub>, increased high affinity viral neutralizing antibodies, and the generation of long-lasting memory B cells in mice (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B19" ref-type="bibr">19</xref>). Additionally, Alum was formulated with the inactivated and VLP vaccines containing E, M, and N proteins (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>) (<xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>) that showed enhanced IgG<sub>1</sub> and neutralizing antibody titers (<xref rid="B14" ref-type="bibr">14</xref>) and prolonged durability (<xref rid="B12" ref-type="bibr">12</xref>). Studies also demonstrated that alum adjuvant plays an essential role in the dose-sparing of CoV vaccines. In a SARS S protein subunit vaccine, the alum-adjuvanted S protein (1 &#956;g) group showed neutralizing antibody titers similar to or higher than the non-adjuvanted S protein (50 &#956;g) group. The alum-adjuvanted S protein (5 &#956;g) group showed a geometric mean titer (GMT) twice as high as the non-adjuvanted S protein (50 &#956;g) group (<xref rid="B20" ref-type="bibr">20</xref>). It should also be noted that different types of alum were selected in the studies, including Alhydrogel, which is chemically crystalline aluminum oxyhydroxide (<xref rid="B43" ref-type="bibr">43</xref>), aluminum hydroxide (<xref rid="B11" ref-type="bibr">11</xref>), aluminum phosphate (<xref rid="B22" ref-type="bibr">22</xref>), and Imject&#8482; Alum (<xref rid="B23" ref-type="bibr">23</xref>), which is a mixture of aluminum hydroxide and magnesium hydroxide. Even though there is no specific description regarding the aluminum hydroxide in reported literature (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B21" ref-type="bibr">21</xref>), it can also be referred to Aluminum oxyhydroxide (<xref rid="B44" ref-type="bibr">44</xref>). However, these studies lacked systematic comparisons with regards to their adjuvanticity and how various alum-based adjuvants differed in their ability to induce neutralizing antibodies.</p><p>It is worth noting that inactivated SARS-CoV or S protein-based vaccines are associated with Th2-type immunopathology, which is characterized by an increase in eosinophils and inflammatory infiltrates (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Moreover, the addition of alum adjuvant exacerbated the immunopathologic reactions (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B45" ref-type="bibr">45</xref>). In alum-adjuvanted SARS-CoV double-inactivated vaccine (DIV), there was a skew in the N or S protein-specific antibodies toward IgG<sub>1</sub>, when compared with the more balanced antibody production in the nonadjuvanted DIV vaccine (<xref rid="B14" ref-type="bibr">14</xref>). These observations raise significant concerns regarding the safety of adjuvanted coronavirus vaccines. On the other hand, it has been shown that alum can reduce immunopathology in SARS-CoV vaccines containing either a double-inactivated virus or S protein (<xref rid="B11" ref-type="bibr">11</xref>). Furthermore, in a recent study, a purified inactivated SARS-CoV-2 vaccine (PiCoVacc) adjuvanted with aluminum hydroxide conferred complete protection in non-human primates (rhesus macaques) with potent humoral responses but without lung immunopathology (<xref rid="B15" ref-type="bibr">15</xref>). This finding raises the question of the mechanism of eosinophilic immunopathology. While commonly thought of as the product of Th2 responses, recent studies have indicated that tissue eosinophilia can also be controlled by Th17 responses (<xref rid="B46" ref-type="bibr">46</xref>). Thus, the proper selection of CoV antigens and adjuvants that can shift host responses away from a Th17-bias appears to be critical. In addition, other studies have demonstrated that the Th2 immunopathology may be associated with SARS N or S protein that results in enhanced eosinophilic immunopathology (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B47" ref-type="bibr">47</xref>). However, more studies are required, as the preliminary data is limited. Additionally, the Th-2&#8211;biased immune responses may raise the concern on vaccine-enhanced respiratory disease (VAERD) (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B48" ref-type="bibr">48</xref>), however, there are no evidences that alum-adjuvanted CoV vaccines show the effect.</p><p>When alum was used as an adjuvant in CoV vaccines (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>), there was a lack of Th1 CD4<sup>+</sup> T cell and cytotoxic CD8<sup>+</sup> T cell immune responses, which is typical for alum-adjuvanted vaccines (<xref rid="B49" ref-type="bibr">49</xref>). However, recent study has demonstrated that the SARS-CoV-2&#8211;specific adaptive immune response correlated with milder disease, indicating that coordinated CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses play a synergistic effect in the protective immunity of COVID-19 (<xref rid="B33" ref-type="bibr">33</xref>). Several other adjuvants, which are capable of inducing more balanced Th1/Th2 or Th1-biased immune responses, have been formulated in CoV vaccines and will be discussed in the following sections.</p></sec><sec id="s3"><title>Emulsion Adjuvants</title><p>The emulsion adjuvants, MF59, and AS03 have already been used in licensed human vaccines to improve the immunogenicity of the antigens (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>). Compared with alum that lacks the capability to mediate cell-mediated immunity (<xref rid="B49" ref-type="bibr">49</xref>), MF59 and AS03 can elicit more balanced immunity, possibly by improving antigen uptake, recruiting immune cells, and promoting the migration of activated antigen-presenting cells (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B52" ref-type="bibr">52</xref>). Emulsion adjuvants have already been used in preclinical studies of vaccines against coronavirus. MF59 used in inactivated SARS and MERS vaccines, as well as vaccines containing the RBD domain of the MERS-CoV spike (S) protein, has exhibited excellent adjuvanticity, with potent humoral immune responses, <italic toggle="yes">i.e.</italic>, high titers of neutralizing antibodies, and cell-mediated immunity in the coronavirus vaccines (<xref rid="B53" ref-type="bibr">53</xref>&#8211;<xref rid="B55" ref-type="bibr">55</xref>). In addition, depending on the types of antigen, cell-mediated immunity induced by MF59 differs. When formulated with the MERS-CoV S protein, MF59 enhanced both effective CD4<sup>+</sup> and CD8<sup>+</sup> T-cell immune responses. In comparison, when combined with inactivated SARS CoV, MF59 induced significant CD4<sup>+</sup> T cell, but not CD8<sup>+</sup> T cell responses (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>). However, in another study by Zhang et&#160;al., it was demonstrated that when MERS S protein was adjuvanted with MF59, it induced higher IgG<sub>1</sub> and IgG<sub>2a</sub> antibodies with a slightly Th2-biased response (<xref rid="B54" ref-type="bibr">54</xref>). Subsequent studies also showed that ferritin-based MERS-CoV S protein, adjuvanted with MF59, promoted multiple antibody responses, including high levels of IgA antibody titers that resulted in potent mucosal immune responses (<xref rid="B58" ref-type="bibr">58</xref>). A study by Tang <italic toggle="yes">et al.</italic> has indicated that there are no significant differences in the neutralizing activity of the serum derived from mice immunized with MERS S377-588 at 1, 5, and 20 &#956;g in the presence of MF59, suggesting the dose-sparing effect of MF59 when it was formulated with MERS S protein (<xref rid="B57" ref-type="bibr">57</xref>). However, an immunopathologic lung reaction, as well as an increase in IL-5 and IL-13 cytokines, was seen in animal studies using both MF59-adjuvanted and adjuvant-free inactivated MERS-CoV vaccines (<xref rid="B53" ref-type="bibr">53</xref>). It has shown that eosinophil infiltrations with higher Th2-type cytokine secretion aggravated the hypersensitivity-type pulmonary immunopathology when vaccinated with MF59-adjuvanted inactivated virus vaccines as compared with the inactivated virus vaccines alone (<xref rid="B53" ref-type="bibr">53</xref>).</p><p>Another emulsion adjuvant, AS03, elicits both potent humoral and cellular immune responses to an inactivated whole virion SARS-CoV (WI-SARS) vaccines (<xref rid="B59" ref-type="bibr">59</xref>) compared with the virion without adjuvants. Moreover, in the presence of the AS03 adjuvant, an identical trend toward specific CD4<sup>+</sup> T cell responses was observed when immunized with SARS-CoV containing the equivalent of 0.5 or 1.5 &#956;g of S protein (<xref rid="B59" ref-type="bibr">59</xref>). Therefore, the addition of AS03 tends to potentiate the immune responses with a lower dosage of antigen. Considering its capability to induce both arms of the immune system, S protein, RBD domain, and N protein can also be formulated with AS03. Currently, GSK is sharing its AS03 adjuvant with COVID-19 vaccine developers globally (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>Besides MF59 and AS03, other emulsion-based adjuvants such as Freund&#8217;s adjuvant and Montanide ISA51 have also been formulated in CoV vaccines (<xref rid="B54" ref-type="bibr">54</xref>). By evaluating the titers of specific serum antibody responses, it has been demonstrated that Freund&#8217;s adjuvant and ISA51 elicited significant Th1 antibody responses (IgG<sub>2a</sub>) with no clear Th2 responses (IgG<sub>1</sub>) (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B59" ref-type="bibr">59</xref>).</p></sec><sec id="s4"><title>TLR Agonists and Other Adjuvants</title><p>Toll-like receptors (TLRs), a category of pattern-recognition receptors, are critical to pathogen recognition. This allows for rapid activation of innate immunity, and subsequently, effective adaptive immunity. TLR agonists have been extensively studied as vaccine adjuvants (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>). CpG, Poly I:C, glucopyranosyl lipid A (GLA), and resiquimod (R848) are agonists for TLR9, TLR3, TLR4, and TLR7/8, respectively. These adjuvants have been evaluated in candidate vaccines against SARS CoV (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>).</p><p>In addition to neutralizing antibodies and CD4<sup>+</sup> T cells, optimal protection against coronavirus probably involves the synergistic effect of CD8<sup>+</sup> T cells (<xref rid="B64" ref-type="bibr">64</xref>). Memory CD8<sup>+</sup> T cells solve the problem of neutralizing antibodies only existing for short periods and providing long-term protective cellular immunity (<xref rid="B64" ref-type="bibr">64</xref>). Among the TLR agonists, CpG significantly augments the CD8<sup>+</sup> T cell immune response higher than the others (<xref rid="B63" ref-type="bibr">63</xref>). Indeed, it has been demonstrated that CpG can also stimulate enhanced IgG production in animals immunized with an inactivated SARS-CoV vaccine (<xref rid="B62" ref-type="bibr">62</xref>). In addition to IgG, IgA production was also enhanced, only when CpG was administered <italic toggle="yes">via</italic> intranasal (<italic toggle="yes">i.n.</italic>) administration (<xref rid="B62" ref-type="bibr">62</xref>), indicating immune activation in the mucosal compartment. Although CpG is capable of inducing both cellular and humoral immune responses, it preferentially induces responses that are Th1-biased. Moreover, CpG can divert pre-existing Th2 responses to a Th1 phenotype, which has laid a foundation for the combination of CpG with other adjuvants, most commonly alum (<xref rid="B65" ref-type="bibr">65</xref>). In SARS-CoV or MERS-CoV subunit vaccines, studies have found that the combination of alum and CpG elicited higher neutralization antibody titers and a more robust cellular immune response compared with alum alone or alum with other TLR agonists (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). In addition to alum, CpG is combined with Montanide ISA-51, a type of water-in-oil emulsion adjuvant. When the combined adjuvants were formulated with SARS S or N protein, they were capable of promoting robust neutralizing antibody production (<xref rid="B66" ref-type="bibr">66</xref>). However, vaccinated with only SARS N protein, animals showed immune responses biased dramatically toward Th1 (<xref rid="B67" ref-type="bibr">67</xref>). In addition, it is reported that R848 could enhance antigen-specific CTL response and induce a fast, robust and durable IFN-&#945; production <italic toggle="yes">in vivo</italic> among humanized mice, which is distinct from the experimental findings based on common mouse models (<xref rid="B68" ref-type="bibr">68</xref>). However, further studies on R848 adjuvanticity should stress more on vaccine formulation. A recent study by Gadd <italic toggle="yes">et al.</italic> indicated that only when R848 was conjugated with DOPE (1,2&#8722;di&#8722;(9Z&#8722;octadecenoyl)&#8722;sn&#8722;glycero&#8722;3&#8722;phosphoethanolamine):DDA (dimethyldioctadecylammonium bromide salt) multilamella liposomes rather than linear mixed, a high potency of immunostimulatory activity was observed (<xref rid="B69" ref-type="bibr">69</xref>). Moreover, an R848-encapsulating PLGA nanoparticle can bring down the excessive level of inflammatory cytokines induced by free R848, which could be benefit to provide long-term safety and appropriate immune response (<xref rid="B70" ref-type="bibr">70</xref>).</p><p>Although CpG had been shown to exhibit considerable potential as a coronavirus-specific adjuvant, studies have found that it might be a poor inducer of long-term immune memory (<xref rid="B46" ref-type="bibr">46</xref>). A recent study indicated that single-stranded RNAs (ssRNAs) derived from the Cricket paralysis virus (CrPV) intergenic region (IGR) internal ribosome entry sites (IRES) could function as vaccine adjuvants endowing long-lasting immunity. This adjuvant significantly activates innate immune response through activating TLR7 and enhancing the chemotaxis of professional antigen-presenting cells (APC) (<xref rid="B71" ref-type="bibr">71</xref>). Moreover, some novel adjuvants such as STING agonist, Advax, and AS01<sub>B</sub>, which is an adjuvant formulated in recombinant zoster vaccine Shingrix, exhibit advantages for long-lasting immune responses (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B72" ref-type="bibr">72</xref>). Advax, a delta inulin microparticle adjuvant, augmented the induction of neutralizing antibodies along with the existence of memory B cells and a robust, long-lasting T-cell IFN-&#947; response when it was formulated in recombinant or inactivated SARS-CoV vaccines (<xref rid="B46" ref-type="bibr">46</xref>). Moreover, Matrix M1, a saponin-based adjuvant, has been demonstrated to be more effective than alum adjuvant in inducing neutralizing antibodies to SARS S protein or MERS S protein (<xref rid="B17" ref-type="bibr">17</xref>). This might address the concern that S protein may lead to antibody-dependent enhancement (ADE), which is more likely to be triggered by mild antibody production (<xref rid="B36" ref-type="bibr">36</xref>).</p><p>The SARS-CoV-2 infections occur at the mucosal surface of the upper respiratory tract (<xref rid="B73" ref-type="bibr">73</xref>). Thus, the elicitation of protective immune responses at the mucosa is critical. TLR agonists, such as flagellin (<xref rid="B74" ref-type="bibr">74</xref>) and CpG ODN (<xref rid="B62" ref-type="bibr">62</xref>), have been used as mucosal adjuvants. As discussed above, the CpG ODN can elicit neutralizing antibodies in mucosal compartments (<xref rid="B62" ref-type="bibr">62</xref>) when formulated with inactivated SARS-CoV. Additionally, the STING agonist, bis-(3&#8242;,5&#8242;)-cyclic dimeric guanosine monophosphate (c-di-GMP or cdGMP), has been reported as a potent mucosal vaccine adjuvant that induces Th1 and Th17 cytokines in a plant-derived H5 influenza vaccine after intranasal vaccination (<xref rid="B75" ref-type="bibr">75</xref>). In a very recent study, it was demonstrated that pulmonary surfactant&#8211;biomimetic liposomes encapsulating STING agonists could be used as mucosal adjuvants for universal influenza vaccines that trigger rapid humoral and cellular immune responses and exhibit sustained cross-protection against influenza (<xref rid="B76" ref-type="bibr">76</xref>). Though cdGMP in polymeric nanoparticle formulations has been used as adjuvants with MERS-CoV S-RBD protein, its ability to induce mucosal immunity was not specifically examined (<xref rid="B72" ref-type="bibr">72</xref>). Thus, further studies are warranted to examine both the efficacy and safety of mucosal adjuvants in coronavirus vaccines.</p></sec><sec id="s5"><title>Conclusion and Perspectives</title><p>In this article, we provided an overview of previously studied adjuvants in candidate inactivated and subunit coronavirus vaccines with a focus on the types of adjuvants in the vaccine formulations and the nature of immune responses to the formulated vaccines. These previous studies provided a convenient basis for the screening of adjuvants required to develop coronavirus vaccines. In-depth reviews of the various adjuvants, a comprehensive understanding of their impacts on the extent and types of immune responses, and an exploration of their combinations with various antigen types and vaccine platforms will facilitate the selection of adjuvants that provide the required immunological protection of coronavirus vaccines.</p><p>In the absence of a cure for COVD-19, effective and safe vaccines are urgently required. Adjuvants such as aluminum-based salts, TLR agonists, emulsions, and other novel adjuvants have distinctive physicochemical properties, which can be significant in regulating the strength, duration, and types of immune responses (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B77" ref-type="bibr">77</xref>). Studies have suggested that neutralizing antibodies are critical for immune protection (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B42" ref-type="bibr">42</xref>).While mechanistic studies are still being conducted, emerging evidence has suggested that SRAS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells in coordination with neutralizing antibodies are required for generating protective immunity against SARS-CoV-2 (<xref rid="B33" ref-type="bibr">33</xref>). Thus, the appropriate adjuvants should be selected to formulate specific antigens that will achieve optimal immunogenicity profiles. Current available studies have demonstrated the feasibility of formulating S protein, RBD domain, M protein and N protein with specific adjuvants.</p><p>It should be noted that the development of a COVID-19 vaccine has been on a fast track. Thus far, four non-replicating viral vector vaccines, three inactivated vaccines and two mRNA vaccines being under clinical phase III stage, with more are on the way (<xref rid="B32" ref-type="bibr">32</xref>). Though different types of adjuvants have been used in exploratory and pre-clinical studies (<xref rid="T1" ref-type="table">
<bold>Tables 1</bold>
</xref>&#8211;<xref rid="T3" ref-type="table">
<bold>3</bold>
</xref>), considering the need for rapid deployment of COVID-19 vaccines for the pandemic, alum, which had been formulated in many other licensed vaccines, have been prioritized (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). In addition to the adjuvants described above, engineered nanomaterials also shed light adjuvant development. It has been shown that physicochemical characteristics of aluminum oxyhydroxide could affect the optimal immunogenicity profiles of vaccine formulations (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). Moreover, a recent study has shown that an alum-stabilized Pickering emulsion (PAPE) showed robust RBD-specific IgG<sub>1</sub> and IgG<sub>2a</sub> titers and a high level of inducing IFN-&#947;-secreting T cells in a COVID-19 vaccine. Additionally, it has been shown that a natural and potent STING agonist encapsulated by pulmonary biomimetic liposomes triggered rapid humoral and cellular immune responses and exhibited a sustained cross-protection against influenza (<xref rid="B76" ref-type="bibr">76</xref>). However, more comprehensive mechanistic studies, including the nature of protective immune responses and screening of the various combinations of antigens and adjuvants, are needed for the successful development of a safe and effective COVID-19 vaccine.</p><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Emulsion adjuvants used in the coronavirus vaccine formulations under exploratory and pre-clinical investigations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Adjuvant Type</th><th valign="top" align="center" rowspan="1" colspan="1">Platform</th><th valign="top" align="center" rowspan="1" colspan="1">Adjuvant</th><th valign="top" align="center" rowspan="1" colspan="1">Antigen</th><th valign="top" align="center" rowspan="1" colspan="1">Antigen Dose</th><th valign="top" colspan="8" align="center" rowspan="1">Immunological response</th><th valign="top" align="center" rowspan="1" colspan="1">Route</th><th valign="top" align="center" rowspan="1" colspan="1">Immunization Schedule</th><th valign="top" align="center" rowspan="1" colspan="1">Safety</th><th valign="top" align="center" rowspan="1" colspan="1">Animal model</th><th valign="top" align="center" rowspan="1" colspan="1">Ref.</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Nab</th><th valign="top" align="center" rowspan="1" colspan="1">IgG<sub>1</sub>
</th><th valign="top" align="center" rowspan="1" colspan="1">IgG<sub>2a</sub>
</th><th valign="top" align="center" rowspan="1" colspan="1">IgA</th><th valign="top" align="center" rowspan="1" colspan="1">Th1 cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">Th2 cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">Th17 Cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">CD8<sup>+</sup> T cell response</th><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Emulsion adjuvants</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59-like</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated MERS virus</td><td valign="top" align="left" rowspan="1" colspan="1">100 &#956;l (1&#215;10<sup>7</sup> TCID<sub>50</sub>/ml)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Lung immunopathology</td><td valign="top" align="center" rowspan="1" colspan="1">hCD26/DPP4 Tg mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B53" ref-type="bibr">53</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated SARS virus</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B56" ref-type="bibr">56</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">AS03</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated SARS virus</td><td valign="top" align="left" rowspan="1" colspan="1">100 &#956;L of WI-SARS containing the equivalent of 0.5/1.0/1.5 &#956;g of S protein</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B59" ref-type="bibr">59</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD-Fc protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice; Ad5-hDPP4 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B54" ref-type="bibr">54</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD-Fc protein</td><td valign="top" align="left" rowspan="1" colspan="1">1/5/20 &#956;g (optimal: 1 &#956;g)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B57" ref-type="bibr">57</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59-like</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD-Fc protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Weight loss and death of mice</td><td valign="top" align="center" rowspan="1" colspan="1">hCD26/DPP4 Tg mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B78" ref-type="bibr">78</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD-Fc protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice; hDPP4-Tg mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B79" ref-type="bibr">79</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59-like</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD-Fc protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">CD26/hDPP4 Tg mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B55" ref-type="bibr">55</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD-Fd protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice; hDPP4-Tg mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B80" ref-type="bibr">80</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59-like</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD protein NPs</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B58" ref-type="bibr">58</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59-like</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">C57BL/6 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B72" ref-type="bibr">72</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">MF59-like</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV/SARS-CoV/SARS-CoV-2 RBD-sc-dimer</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B23" ref-type="bibr">23</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">Montanide ISA51</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD-Fc protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice; Ad5-hDPP4 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B54" ref-type="bibr">54</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">Freund's adjuvant</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S-RBD-Fc protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice; Ad5-hDPP4 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B54" ref-type="bibr">54</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">Ribi adjuvants</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV S1 protein</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B22" ref-type="bibr">22</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">Alum-<break/>stabilized Pickering emulsion (PAPE)</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant RBD of<break/>SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Acceptable biosafety</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B81" ref-type="bibr">81</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>Annotation:</p></fn><fn><p>
<bold>MF59 adjuvant</bold> an emulsion adjuvant composed of an oil phase (squalene:4.3%): and an aqueous phase (polysorbate 80:0.5%, sorbitan trioleate:0.5%);</p></fn><fn><p>
<bold>MF59-like</bold> (AddaVax): a squalene-based oil-in-water nano-emulsion based on the formulation of MF59 (squalene:5%, polysorbate 80:0.5%, and sorbitan trioleate:0.5%);</p></fn><fn><p>
<bold>AS03 adjuvant</bold>: an emulsion adjuvant composed of an oil phase (10.69 mg squalene, 11.86 mg DL-&#945;-tocopherol) and an aqueous phase (4.86 mg polysorbate 80) each 0.5-mL adult dose;</p></fn><fn><p>
<bold>Ribi adjuvant</bold>: an oil-in-water emulsion containing 2% squalene-Tween 80-water, 0.5 mg monophosphoryl lipid A, and 0.5 mg synthetic trehalose dicorynomycolate;</p></fn><fn><p>
<bold>Montanide ISA-51</bold>: a water-in-oil (w/o) emulsion adjuvant composed of a mineral oil and a surfactant from the mannide monooleate family;</p></fn><fn><p>
<bold>Freund&#8217;s adjuvant</bold>: heat-killed mycobacterium tuberculosis in non-metabolizable oils (paraffin oil and mannide monooleate);</p></fn><fn><p>
<bold>Nab</bold> represents the neutralizing antibodies, and N/A means not available.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3</label><caption><p>TLR agonists and other adjuvants used in the coronavirus vaccine formulations under exploratory and pre-clinical investigations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" rowspan="2" align="left" colspan="1">Adjuvant Type</th><th valign="top" rowspan="2" align="center" colspan="1">Platform</th><th valign="top" rowspan="2" align="center" colspan="1">Adjuvant</th><th valign="top" rowspan="2" align="center" colspan="1">Antigen</th><th valign="top" rowspan="2" align="center" colspan="1">Antigen Dose</th><th valign="top" colspan="8" align="center" rowspan="1">Immunological response</th><th valign="top" rowspan="2" align="center" colspan="1">Route</th><th valign="top" rowspan="2" align="center" colspan="1">Immunization Schedule</th><th valign="top" rowspan="2" align="center" colspan="1">Safety</th><th valign="top" rowspan="2" align="center" colspan="1">Animal model</th><th valign="top" rowspan="2" align="center" colspan="1">Ref.</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Nab</th><th valign="top" align="center" rowspan="1" colspan="1">IgG<sub>1</sub>
</th><th valign="top" align="center" rowspan="1" colspan="1">IgG<sub>2a</sub>
</th><th valign="top" align="center" rowspan="1" colspan="1">IgA</th><th valign="top" align="center" rowspan="1" colspan="1">Th1 cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">Th2 cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">Th17 Cytokines</th><th valign="top" align="center" rowspan="1" colspan="1">CD8<sup>+</sup> T cell response</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR agonists</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">CpG ODN 2006</td><td valign="top" align="center" rowspan="1" colspan="1">inactivated SARS-CoV(SARS-CoV Z-1 strain virus)</td><td valign="top" align="center" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">i.n./i.p.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B62" ref-type="bibr">62</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Monophosphoryl lipid A</td><td valign="top" align="center" rowspan="1" colspan="1">MERS-CoV S-RBD-Fc protein</td><td valign="top" align="center" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice; Ad5-hDPP4 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B54" ref-type="bibr">54</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">CpG ODN 1826</td><td valign="top" align="center" rowspan="1" colspan="1">SARS S peptide (HLA-A*0201 restricted)</td><td valign="top" align="center" rowspan="1" colspan="1">20 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" rowspan="1" align="center" colspan="1">HLA-A*0201 Tg mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B63" ref-type="bibr">63</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Poly(I:C)</td><td valign="top" align="center" rowspan="1" colspan="1">SARS S peptide (HLA-A*0201 restricted)</td><td valign="top" align="center" rowspan="1" colspan="1">20 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B63" ref-type="bibr">63</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">R848</td><td valign="top" align="center" rowspan="1" colspan="1">SARS S peptide (HLA-A*0201 restricted)</td><td valign="top" align="center" rowspan="1" colspan="1">20 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B63" ref-type="bibr">63</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">CpG ODN 1826 + Alhydrogel</td><td valign="top" align="center" rowspan="1" colspan="1">SARS S protein</td><td valign="top" align="center" rowspan="1" colspan="1">8 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">129S6/SvEv mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B19" ref-type="bibr">19</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">CpG+aluminum oxyhydroxide</td><td valign="top" align="center" rowspan="1" colspan="1">MERS S protein</td><td valign="top" align="center" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B18" ref-type="bibr">18</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">CpG+ Montanide ISA-51</td><td valign="top" align="center" rowspan="1" colspan="1">SARS S protein</td><td valign="top" align="center" rowspan="1" colspan="1">30 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B66" ref-type="bibr">66</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">CpG+ Montanide ISA-51</td><td valign="top" align="center" rowspan="1" colspan="1">SARS N protein</td><td valign="top" align="center" rowspan="1" colspan="1">50 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c<break/>mice; Macaques</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B67" ref-type="bibr">67</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">GLA+ Alhydrogel or aluminum phosphate</td><td valign="top" align="center" rowspan="1" colspan="1">RBD (S318-510) of the SARS-CoV S protein</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c<break/>mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B82" ref-type="bibr">82</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">ssRNA+<break/>aluminum hydroxide</td><td valign="top" align="center" rowspan="1" colspan="1">MERS-CoV S protein</td><td valign="top" align="center" rowspan="1" colspan="1">1 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">hDPP4 Tg mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B71" ref-type="bibr">71</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Others</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">AS01<sub>B</sub>
</td><td valign="top" align="center" rowspan="1" colspan="1">SARS inactivated whole virus</td><td valign="top" align="center" rowspan="1" colspan="1">0.5/1 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#215;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c<break/>mice; Hamsters</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B59" ref-type="bibr">59</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Inactivated vaccines /Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Advax</td><td valign="top" align="center" rowspan="1" colspan="1">SARS S protein/inactivated whole virus</td><td valign="top" align="center" rowspan="1" colspan="1">1 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c<break/>mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B46" ref-type="bibr">46</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">Matrix M1</td><td valign="top" align="center" rowspan="1" colspan="1">SARS S protein/MERS S protein</td><td valign="top" align="center" rowspan="1" colspan="1">1/3/10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">i.m.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">BALB/c<break/>mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B17" ref-type="bibr">17</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
</td><td valign="top" align="center" rowspan="1" colspan="1">Subunit vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">NP-cdGMP</td><td valign="top" align="center" rowspan="1" colspan="1">MERS-CoV S-RBD protein</td><td valign="top" align="center" rowspan="1" colspan="1">10 &#956;g</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8730;</td><td valign="top" align="center" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">N/A</td><td valign="top" align="center" rowspan="1" colspan="1">C57BL/6 mice</td><td valign="top" align="center" rowspan="1" colspan="1"> (<xref rid="B72" ref-type="bibr">72</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p>Annotation:</p></fn><fn><p>
<bold>MPLA</bold> (monophosphoryl lipid A): a low-toxicity derivative of lipopolysaccharide (LPS), that retains the immunologically active lipid A portion of the parent molecule;</p></fn><fn><p>
<bold>CpG ODN</bold>: synthetic oligodeoxynucleotides containing unmethylated CpG motifs;</p></fn><fn><p>
<bold>PolyI:C</bold> (Polyinosinic-polycytidylic acid): a synthetic analog of double-stranded RNA (dsRNA), a molecular pattern associated with viral infection;</p></fn><fn><p>
<bold>R848</bold> (resiquimod): a small molecular weight imidazoquinoline compound, an immune response modifier with potent antiviral and antitumor activities;</p></fn><fn><p>
<bold>GLA</bold>: glucopyranosyl lipid A, a synthetic Toll-like receptor 4 (TLR4) agonist;</p></fn><fn><p>
<bold>Advax</bold>: a novel microcrystalline polysaccharide particle engineered from delta inulin;</p></fn><fn><p>
<bold>AS01<sub>B</sub></bold>: a liposome-based emulsion adjuvant system containing two immunostimulants, 3-O-desacyl-4&#8242;-monophosporyl lipid A (MPL) and the saponin QS-21;</p></fn><fn><p>
<bold>Matrix M1</bold>: consists of two individually formed 40-nm-sized particles, each with a different and well-characterized saponin fraction (Fraction-A and Fraction-C);</p></fn><fn><p>
<bold>NP-cdGMP</bold>: cyclic diguanylate monophosphate (cdGMP), a canonical STING (stimulator of interferon genes) agonist, encapsulated into PLGA-based hollow nanoparticles.</p></fn><fn><p>
<bold>Nab</bold> represents the neutralizing antibodies, and N/A means not available.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s6"><title>Author Contributions</title><p>ZLiang, HZhu, XW, BJ, and XX wrote the manuscript. BS, LS and HZeng conceived and revised the manuscript. HS, YY, and WZ provided critical suggestions. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="funding-information" id="s7"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (31870919), Natural Science Foundation of Liaoning Province (No. 20180550597), LiaoNing Revitalization Talents Program (XLYC1807113), Dalian Science and Technology Innovation Fund (No. 2020JJ25CY015), and Fundamental Research Funds for the Central Universities (DUT19TD12).</p></sec><sec id="s8"><title>Conflict of Interest</title><p>WZ was employed by NCPC Genetech Biotechnology Co., Ltd. LS was employed by Shanghai Zerun Biotechnology Co., Ltd.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fehr</surname><given-names>AR</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title>. <source>Methods Mol Biol</source> (<year>2015</year>) <volume>1282</volume>:<fpage>1</fpage>&#8211;<lpage>23</lpage>. &#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmid">25720466</pub-id><pub-id pub-id-type="pmcid">PMC4369385</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name></person-group><article-title>Timely development of vaccines against SARS-CoV-2</article-title>. <source>Emerg Microbes Infect</source> (<year>2020</year>) <volume>9</volume>:<page-range>542&#8211;4</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/22221751.2020.1737580</pub-id><pub-id pub-id-type="pmcid">PMC7144304</pub-id><pub-id pub-id-type="pmid">32148172</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>EHY</given-names></name><name name-style="western"><surname>Hsiung</surname><given-names>CA</given-names></name><name name-style="western"><surname>Cowling</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>LM</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>T</given-names></name><etal/></person-group><article-title>A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan</article-title>. <source>BMC Infect Dis</source> (<year>2010</year>) <volume>10</volume>:<elocation-id>50</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1186/1471-2334-10-50</pub-id><pub-id pub-id-type="pmid">20205928</pub-id><pub-id pub-id-type="pmcid">PMC2846944</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Middle East respiratory syndrome coronavirus (MERS-CoV)</source> (<year>2020</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.who.int/emergencies/mers-cov/en/">http://www.who.int/emergencies/mers-cov/en/</uri> (Accessed <date-in-citation>October 1, 2020</date-in-citation>).</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>WHO COVID-19 dashboard</source> (<year>2020</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</uri> (Accessed <date-in-citation>October 1, 2020</date-in-citation>).</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Garner</surname><given-names>LV</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>SP</given-names></name><name name-style="western"><surname>Carter</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases</article-title>. <source>ACS Cent Sci</source> (<year>2020</year>) <volume>6</volume>:<page-range>315&#8211;31</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acscentsci.0c00272</pub-id><pub-id pub-id-type="pmcid">PMC10467574</pub-id><pub-id pub-id-type="pmid">32226821</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name name-style="western"><surname>Purushotham</surname><given-names>JN</given-names></name><name name-style="western"><surname>Port</surname><given-names>JR</given-names></name><etal/></person-group><article-title>ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title>. <source>BioRxiv</source> (<year>2020</year>) <volume>586</volume>:<page-range>578&#8211;82</page-range>. &#160;<pub-id pub-id-type="doi">10.1101/2020.05.13.093195</pub-id><pub-id pub-id-type="pmcid">PMC8436420</pub-id><pub-id pub-id-type="pmid">32731258</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasaro</surname><given-names>MO</given-names></name><name name-style="western"><surname>Ertl</surname><given-names>HC</given-names></name></person-group><article-title>New insights on adenovirus as vaccine vectors</article-title>. <source>Mol Ther</source> (<year>2009</year>) <volume>17</volume>:<page-range>1333&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/mt.2009.130</pub-id><pub-id pub-id-type="pmcid">PMC2835230</pub-id><pub-id pub-id-type="pmid">19513019</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koirala</surname><given-names>A</given-names></name><name name-style="western"><surname>Joo</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Khatami</surname><given-names>A</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>C</given-names></name><name name-style="western"><surname>Britton</surname><given-names>PN</given-names></name></person-group><article-title>Vaccines for COVID-19: The current state of play</article-title>. <source>Paediatr Respir Rev</source> (<year>2020</year>) <volume>35</volume>:<page-range>43&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.prrv.2020.06.010</pub-id><pub-id pub-id-type="pmcid">PMC7301825</pub-id><pub-id pub-id-type="pmid">32653463</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okba</surname><given-names>NM</given-names></name><name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches</article-title>. <source>Curr Opin Virol</source> (<year>2017</year>) <volume>23</volume>:<fpage>49</fpage>&#8211;<lpage>58</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.coviro.2017.03.007</pub-id><pub-id pub-id-type="pmid">28412285</pub-id><pub-id pub-id-type="pmcid">PMC7102752</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name><name name-style="western"><surname>Sbrana</surname><given-names>E</given-names></name><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Newman</surname><given-names>PC</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T</given-names></name><name name-style="western"><surname>Atmar</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e35421</fpage>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0035421</pub-id><pub-id pub-id-type="pmid">22536382</pub-id><pub-id pub-id-type="pmcid">PMC3335060</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takasuka</surname><given-names>N</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>H</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>M</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Itamura</surname><given-names>S</given-names></name><etal/></person-group><article-title>A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice</article-title>. <source>Int Immunol</source> (<year>2004</year>) <volume>16</volume>:<page-range>1423&#8211;30</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/intimm/dxh143</pub-id><pub-id pub-id-type="pmcid">PMC7108621</pub-id><pub-id pub-id-type="pmid">15314040</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spruth</surname><given-names>M</given-names></name><name name-style="western"><surname>Kistner</surname><given-names>O</given-names></name><name name-style="western"><surname>Savidis-Dacho</surname><given-names>H</given-names></name><name name-style="western"><surname>Hitter</surname><given-names>E</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>B</given-names></name><name name-style="western"><surname>Gerencer</surname><given-names>M</given-names></name><etal/></person-group><article-title>A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<page-range>652&#8211;61</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2005.08.055</pub-id><pub-id pub-id-type="pmcid">PMC7115667</pub-id><pub-id pub-id-type="pmid">16214268</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolles</surname><given-names>M</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D</given-names></name><name name-style="western"><surname>Long</surname><given-names>K</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>M</given-names></name><etal/></person-group><article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title>. <source>J Virol</source> (<year>2011</year>) <volume>85</volume>:<page-range>12201&#8211;15</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JVI.06048-11</pub-id><pub-id pub-id-type="pmcid">PMC3209347</pub-id><pub-id pub-id-type="pmid">21937658</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rapid development of an inactivated vaccine for SARS-CoV-2</article-title>. <source>Science</source> (<year>2020</year>) <volume>369</volume>:<fpage>77</fpage>&#8211;<lpage>81</lpage>. &#160;<pub-id pub-id-type="doi">10.1101/2020.04.17.046375</pub-id><pub-id pub-id-type="pmid">32376603</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2</article-title>. <source>Cell</source> (<year>2020</year>) <volume>182</volume>:<fpage>713</fpage>&#8211;<lpage>21.e9</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.06.008</pub-id><pub-id pub-id-type="pmid">32778225</pub-id><pub-id pub-id-type="pmcid">PMC7275151</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>CM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YV</given-names></name><name name-style="western"><surname>Mu</surname><given-names>H</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>JK</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title>. <source>Vaccine</source> (<year>2014</year>) <volume>32</volume>:<page-range>3169&#8211;74</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmcid">PMC4058772</pub-id><pub-id pub-id-type="pmid">24736006</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>:<fpage>e112602</fpage>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0112602</pub-id><pub-id pub-id-type="pmid">25405618</pub-id><pub-id pub-id-type="pmcid">PMC4236105</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zakhartchouk</surname><given-names>AN</given-names></name><name name-style="western"><surname>Sharon</surname><given-names>C</given-names></name><name name-style="western"><surname>Satkunarajah</surname><given-names>M</given-names></name><name name-style="western"><surname>Auperin</surname><given-names>T</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G</given-names></name><etal/></person-group><article-title>Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<page-range>136&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.084</pub-id><pub-id pub-id-type="pmcid">PMC7115608</pub-id><pub-id pub-id-type="pmid">16919855</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Post</surname><given-names>P</given-names></name><name name-style="western"><surname>Chubet</surname><given-names>R</given-names></name><name name-style="western"><surname>Holtz</surname><given-names>K</given-names></name><name name-style="western"><surname>McPherson</surname><given-names>C</given-names></name><name name-style="western"><surname>Petric</surname><given-names>M</given-names></name><etal/></person-group><article-title>A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<page-range>3624&#8211;31</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.01.059</pub-id><pub-id pub-id-type="pmcid">PMC7115485</pub-id><pub-id pub-id-type="pmid">16497416</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge</article-title>. <source>Ebiomedicine</source> (<year>2015</year>) <volume>2</volume>:<page-range>1438&#8211;46</page-range>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2015.08.031</pub-id><pub-id pub-id-type="pmcid">PMC4634622</pub-id><pub-id pub-id-type="pmid">26629538</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title>. <source>Nat Commun</source> (<year>2015</year>) <volume>6</volume>:<fpage>7712</fpage>. &#160;<pub-id pub-id-type="doi">10.1038/ncomms8712</pub-id><pub-id pub-id-type="pmid">26218507</pub-id><pub-id pub-id-type="pmcid">PMC4525294</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E</given-names></name><etal/></person-group><article-title>A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS</article-title>. <source>Cell</source> (<year>2020</year>) <volume>182</volume>:<page-range>722&#8211;33</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.06.035</pub-id><pub-id pub-id-type="pmcid">PMC7321023</pub-id><pub-id pub-id-type="pmid">32645327</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity</article-title>. <source>Nature</source> (<year>2020</year>) <volume>586</volume>:<page-range>572&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2599-8</pub-id><pub-id pub-id-type="pmid">32726802</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>The spike protein of SARS-CoV&#8211;a target for vaccine and therapeutic development</article-title>. <source>Nat Rev Microbiol</source> (<year>2009</year>) <volume>7</volume>:<page-range>226&#8211;36</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nrmicro2090</pub-id><pub-id pub-id-type="pmcid">PMC2750777</pub-id><pub-id pub-id-type="pmid">19198616</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites</article-title>. <source>Acta Pharm Sin B</source> (<year>2020</year>) <volume>10</volume>:<page-range>1228&#8211;38</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.apsb.2020.04.009</pub-id><pub-id pub-id-type="pmcid">PMC7194921</pub-id><pub-id pub-id-type="pmid">32363136</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>J</given-names></name><name name-style="western"><surname>Repass</surname><given-names>JF</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>A</given-names></name><name name-style="western"><surname>Makino</surname><given-names>S</given-names></name></person-group><article-title>Membrane topology of coronavirus E protein</article-title>. <source>Virology</source> (<year>2001</year>) <volume>281</volume>:<page-range>163&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1006/viro.2001.0818</pub-id><pub-id pub-id-type="pmcid">PMC7130618</pub-id><pub-id pub-id-type="pmid">11277690</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name></person-group><article-title>Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity</article-title>. <source>Vaccine</source> (<year>2019</year>) <volume>37</volume>:<page-range>3167&#8211;78</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.055</pub-id><pub-id pub-id-type="pmid">31047671</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanh Le</surname><given-names>T</given-names></name><name name-style="western"><surname>Andreadakis</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Gomez Roman</surname><given-names>R</given-names></name><name name-style="western"><surname>Tollefsen</surname><given-names>S</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><etal/></person-group><article-title>The COVID-19 vaccine development landscape</article-title>. <source>Nat Rev Drug Discov</source> (<year>2020</year>) <volume>19</volume>:<page-range>305&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id><pub-id pub-id-type="pmid">32273591</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McPherson</surname><given-names>C</given-names></name><name name-style="western"><surname>Chubet</surname><given-names>R</given-names></name><name name-style="western"><surname>Holtz</surname><given-names>K</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D</given-names></name><name name-style="western"><surname>Cox</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant</article-title>. <source>Methods Mol Biol</source> (<year>2016</year>) <volume>1403</volume>:<page-range>269&#8211;84</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-3387-7_14</pub-id><pub-id pub-id-type="pmcid">PMC7139448</pub-id><pub-id pub-id-type="pmid">27076136</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Development of SARS vaccines and therapeutics is still needed</article-title>. <source>Future Virol</source> (<year>2013</year>) <volume>8</volume>:<fpage>1</fpage>&#8211;<lpage>2</lpage>. &#160;<pub-id pub-id-type="doi">10.2217/fvl.12.126</pub-id><pub-id pub-id-type="pmid">32201503</pub-id><pub-id pub-id-type="pmcid">PMC7079997</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Draft landscape of COVID-19 candidate vaccines</source> (<year>2020</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</uri> (Accessed <date-in-citation>October 1, 2020</date-in-citation>).</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moderbacher</surname><given-names>CR</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></name><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>KM</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity</article-title>. <source>Cell</source> (<year>2020</year>) <volume>183</volume>:<fpage>1</fpage>&#8211;<lpage>17</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.09.038</pub-id><pub-id pub-id-type="pmid">33010815</pub-id><pub-id pub-id-type="pmcid">PMC7494270</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>The potential danger of suboptimal antibody responses in COVID-19</article-title>. <source>Nat Rev Immunol</source> (<year>2020</year>) <volume>20</volume>:<page-range>339&#8211;41</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41577-020-0321-6</pub-id><pub-id pub-id-type="pmcid">PMC7187142</pub-id><pub-id pub-id-type="pmid">32317716</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Kuwahara</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates</article-title>. <source>ACS Infect Dis</source> (<year>2016</year>) <volume>2</volume>:<page-range>361&#8211;76</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00006</pub-id><pub-id pub-id-type="pmcid">PMC7075522</pub-id><pub-id pub-id-type="pmid">27627203</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry</article-title>. <source>J Virol</source> (<year>2020</year>) <volume>94</volume>:<page-range>e02015&#8211;19</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/jvi.02015-19</pub-id><pub-id pub-id-type="pmcid">PMC7022351</pub-id><pub-id pub-id-type="pmid">31826992</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasui</surname><given-names>F</given-names></name><name name-style="western"><surname>Kai</surname><given-names>C</given-names></name><name name-style="western"><surname>Kitabatake</surname><given-names>M</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoneda</surname><given-names>M</given-names></name><name name-style="western"><surname>Yokochi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<page-range>6337&#8211;48</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.181.9.6337</pub-id><pub-id pub-id-type="pmid">18941225</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>GS</given-names></name><name name-style="western"><surname>Tang</surname><given-names>YW</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>KM</given-names></name><name name-style="western"><surname>Colley</surname><given-names>DG</given-names></name></person-group><article-title>Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus</article-title>. <source>J Immunol</source> (<year>1993</year>) <volume>151</volume>:<page-range>2032&#8211;40</page-range>.<pub-id pub-id-type="pmid">8345194</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ito</surname><given-names>A</given-names></name></person-group><article-title>Tailoring inorganic nanoadjuvants towards next-generation vaccines</article-title>. <source>Chem Soc Rev</source> (<year>2018</year>) <volume>47</volume>:<page-range>4954&#8211;80</page-range>. &#160;<pub-id pub-id-type="doi">10.1039/c8cs00028j</pub-id><pub-id pub-id-type="pmid">29911725</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name></person-group><article-title>Recent Advances in Vaccine Adjuvants</article-title>. <source>Pharm Res</source> (<year>2002</year>) <volume>19</volume>:<page-range>715&#8211;28</page-range>. &#160;<pub-id pub-id-type="doi">10.1023/A:1016104910582</pub-id><pub-id pub-id-type="pmid">12134940</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y-P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Engineering an Effective Immune Adjuvant by Designed Control of Shape and Crystallinity of Aluminum Oxyhydroxide Nanoparticles</article-title>. <source>ACS Nano</source> (<year>2013</year>) <volume>7</volume>:<page-range>10834&#8211;49</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/nn404211j</pub-id><pub-id pub-id-type="pmcid">PMC3899397</pub-id><pub-id pub-id-type="pmid">24261790</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heaton</surname><given-names>PM</given-names></name></person-group><article-title>The Covid-19 Vaccine-Development Multiverse</article-title>. <source>N Engl J Med</source> (<year>2020</year>). &#160;<pub-id pub-id-type="doi">10.1056/NEJMe2025111</pub-id><pub-id pub-id-type="pmcid">PMC7377255</pub-id><pub-id pub-id-type="pmid">32663910</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>A</given-names></name></person-group><article-title>Effects of immobilization onto aluminum hydroxide particles on the thermally induced conformational behavior of three model proteins</article-title>. <source>Int J Biol Macromol</source> (<year>2009</year>) <volume>45</volume>:<page-range>80&#8211;5</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2009.04.008</pub-id><pub-id pub-id-type="pmid">19397921</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruwona</surname><given-names>TB</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>AN</given-names></name><name name-style="western"><surname>Shi</surname><given-names>YC</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name></person-group><article-title>Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<page-range>3059&#8211;67</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.081</pub-id><pub-id pub-id-type="pmcid">PMC4920416</pub-id><pub-id pub-id-type="pmid">27155490</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>See</surname><given-names>RH</given-names></name><name name-style="western"><surname>Zakhartchouk</surname><given-names>AN</given-names></name><name name-style="western"><surname>Petric</surname><given-names>M</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Mok</surname><given-names>CP</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus</article-title>. <source>J Gen Virol</source> (<year>2006</year>) <volume>87</volume>:<page-range>641&#8211;50</page-range>. &#160;<pub-id pub-id-type="doi">10.1099/vir.0.81579-0</pub-id><pub-id pub-id-type="pmid">16476986</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D</given-names></name><name name-style="western"><surname>Ong</surname><given-names>CH</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B-H</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C-TK</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name></person-group><article-title>Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology</article-title>. <source>J Virol</source> (<year>2015</year>) <volume>89</volume>:<fpage>2995</fpage>&#8211;<lpage>3007</lpage>. &#160;<pub-id pub-id-type="doi">10.1128/jvi.02980-14</pub-id><pub-id pub-id-type="pmid">25520500</pub-id><pub-id pub-id-type="pmcid">PMC4337527</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deming</surname><given-names>D</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B</given-names></name><name name-style="western"><surname>Davis</surname><given-names>N</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants</article-title>. <source>PLoS Med</source> (<year>2006</year>) <volume>3</volume>:<fpage>e525</fpage>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pmed.0030525</pub-id><pub-id pub-id-type="pmid">17194199</pub-id><pub-id pub-id-type="pmcid">PMC1716185</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotez</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Corry</surname><given-names>DB</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>ME</given-names></name></person-group><article-title>COVID-19 vaccines: neutralizing antibodies and the alum advantage</article-title>. <source>Nat Rev Immunol</source> (<year>2020</year>) <volume>20</volume>:<fpage>399</fpage>&#8211;<lpage>400</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41577-020-0358-6</pub-id><pub-id pub-id-type="pmid">32499636</pub-id><pub-id pub-id-type="pmcid">PMC7271131</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>SL</given-names></name><name name-style="western"><surname>Chui</surname><given-names>P</given-names></name><name name-style="western"><surname>Lim</surname><given-names>B</given-names></name><name name-style="western"><surname>Salto-Tellez</surname><given-names>M</given-names></name></person-group><article-title>Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients</article-title>. <source>Virus Res</source> (<year>2009</year>) <volume>145</volume>:<page-range>260&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.virusres.2009.07.014</pub-id><pub-id pub-id-type="pmcid">PMC7114434</pub-id><pub-id pub-id-type="pmid">19635508</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Ott</surname><given-names>GS</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>A</given-names></name></person-group><article-title>The mechanism of action of MF59 &#8211; An innately attractive adjuvant formulation</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<page-range>4341&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.061</pub-id><pub-id pub-id-type="pmid">22682289</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcon</surname><given-names>N</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>DW</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name></person-group><article-title>Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion</article-title>. <source>Expert Rev Vaccines</source> (<year>2012</year>) <volume>11</volume>:<page-range>349&#8211;66</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/erv.11.192</pub-id><pub-id pub-id-type="pmid">22380826</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morel</surname><given-names>S</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S</given-names></name><name name-style="western"><surname>Baras</surname><given-names>B</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>V</given-names></name><etal/></person-group><article-title>Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>2461&#8211;73</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.011</pub-id><pub-id pub-id-type="pmid">21256188</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>AS</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>K</given-names></name><name name-style="western"><surname>Peng</surname><given-names>BH</given-names></name><etal/></person-group><article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title>. <source>Hum Vaccin Immunother</source> (<year>2016</year>) <volume>12</volume>:<page-range>2351&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2016.1177688</pub-id><pub-id pub-id-type="pmcid">PMC5027702</pub-id><pub-id pub-id-type="pmid">27269431</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title>. <source>Cell Mol Immunol</source> (<year>2016</year>) <volume>13</volume>:<page-range>180&#8211;90</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmcid">PMC4786625</pub-id><pub-id pub-id-type="pmid">25640653</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyon</surname><given-names>MP</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C-TK</given-names></name><name name-style="western"><surname>Seid</surname><given-names>CA</given-names></name><name name-style="western"><surname>Pollet</surname><given-names>J</given-names></name><name name-style="western"><surname>Naceanceno</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen</article-title>. <source>Vaccine</source> (<year>2018</year>) <volume>36</volume>:<page-range>1853&#8211;62</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.065</pub-id><pub-id pub-id-type="pmcid">PMC5860679</pub-id><pub-id pub-id-type="pmid">29496347</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>WP</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>K</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>JB</given-names></name><name name-style="western"><surname>Abrignani</surname><given-names>S</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization</article-title>. <source>J Virol</source> (<year>2005</year>) <volume>79</volume>:<page-range>13915&#8211;23</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JVI.79.22.13915-13923.2005</pub-id><pub-id pub-id-type="pmcid">PMC1280202</pub-id><pub-id pub-id-type="pmid">16254327</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C-TK</given-names></name><etal/></person-group><article-title>Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus</article-title>. <source>Hum Vaccin Immunother</source> (<year>2015</year>) <volume>11</volume>:<page-range>1244&#8211;50</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2015.1021527</pub-id><pub-id pub-id-type="pmcid">PMC4514392</pub-id><pub-id pub-id-type="pmid">25874632</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y-S</given-names></name><name name-style="western"><surname>Son</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>SB</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P</given-names></name><etal/></person-group><article-title>Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>1093</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.01093</pub-id><pub-id pub-id-type="pmid">29868035</pub-id><pub-id pub-id-type="pmcid">PMC5966535</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name><name name-style="western"><surname>Baras</surname><given-names>B</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>G</given-names></name><name name-style="western"><surname>Knott</surname><given-names>I</given-names></name><etal/></person-group><article-title>Immunogenicity and protective efficacy in mice and hamsters of a beta-propiolactone inactivated whole virus SARS-CoV vaccine</article-title>. <source>Viral Immunol</source> (<year>2010</year>) <volume>23</volume>:<page-range>509&#8211;19</page-range>. &#160;<pub-id pub-id-type="doi">10.1089/vim.2010.0028</pub-id><pub-id pub-id-type="pmcid">PMC2967819</pub-id><pub-id pub-id-type="pmid">20883165</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinhagen</surname><given-names>F</given-names></name><name name-style="western"><surname>Kinjo</surname><given-names>T</given-names></name><name name-style="western"><surname>Bode</surname><given-names>C</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>DM</given-names></name></person-group><article-title>TLR-based immune adjuvants</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>3341&#8211;55</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.08.002</pub-id><pub-id pub-id-type="pmcid">PMC3000864</pub-id><pub-id pub-id-type="pmid">20713100</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaisho</surname><given-names>T</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Toll-like receptors as adjuvant receptors</article-title>. <source>Biochim Biophys Acta Mol Cell Res</source> (<year>2002</year>) <volume>1589</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/S0167-4889(01)00182-3</pub-id><pub-id pub-id-type="pmid">11909637</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gai</surname><given-names>W</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Tu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine</article-title>. <source>Viral Immunol</source> (<year>2008</year>) <volume>21</volume>:<fpage>27</fpage>&#8211;<lpage>37</lpage>. &#160;<pub-id pub-id-type="doi">10.1089/vim.2007.0079</pub-id><pub-id pub-id-type="pmid">18355120</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name></person-group><article-title>The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>6670&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.100</pub-id><pub-id pub-id-type="pmcid">PMC7115397</pub-id><pub-id pub-id-type="pmid">21745520</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection</article-title>. <source>J Virol</source> (<year>2014</year>) <volume>88</volume>:<page-range>11034&#8211;44</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JVI.01505-14</pub-id><pub-id pub-id-type="pmcid">PMC4178831</pub-id><pub-id pub-id-type="pmid">25056892</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weeratna</surname><given-names>RD</given-names></name><name name-style="western"><surname>Brazolot Millan</surname><given-names>CL</given-names></name><name name-style="western"><surname>McCluskie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Davis</surname><given-names>HL</given-names></name></person-group><article-title>CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice</article-title>. <source>FEMS Immunol Med Microbiol</source> (<year>2001</year>) <volume>32</volume>:<fpage>65</fpage>&#8211;<lpage>71</lpage>. &#160;<pub-id pub-id-type="doi">10.1111/j.1574-695X.2001.tb00535.x</pub-id><pub-id pub-id-type="pmid">11750224</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lien</surname><given-names>SP</given-names></name><name name-style="western"><surname>Shih</surname><given-names>YP</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HW</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>JP</given-names></name><name name-style="western"><surname>Leng</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Identification of synthetic vaccine candidates against SARS CoV infection</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2007</year>) <volume>358</volume>:<page-range>716&#8211;21</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.bbrc.2007.04.164</pub-id><pub-id pub-id-type="pmcid">PMC7092873</pub-id><pub-id pub-id-type="pmid">17506989</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Leng</surname><given-names>C</given-names></name><name name-style="western"><surname>Lien</surname><given-names>S</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<page-range>3100&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.01.058</pub-id><pub-id pub-id-type="pmcid">PMC7115648</pub-id><pub-id pub-id-type="pmid">16494977</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<page-range>6143&#8211;53</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.09.052</pub-id><pub-id pub-id-type="pmcid">PMC5641266</pub-id><pub-id pub-id-type="pmid">28958808</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gadd</surname><given-names>AJR</given-names></name><name name-style="western"><surname>Castelletto</surname><given-names>V</given-names></name><name name-style="western"><surname>Kabova</surname><given-names>E</given-names></name><name name-style="western"><surname>Shankland</surname><given-names>K</given-names></name><name name-style="western"><surname>Perrie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hamley</surname><given-names>I</given-names></name><etal/></person-group><article-title>High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation</article-title>. <source>Eur J Pharm Sci</source> (<year>2018</year>) <volume>123</volume>:<page-range>268&#8211;76</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ejps.2018.07.048</pub-id><pub-id pub-id-type="pmcid">PMC6137072</pub-id><pub-id pub-id-type="pmid">30048801</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowling</surname><given-names>DJ</given-names></name></person-group><article-title>Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants</article-title>. <source>Immunohorizons</source> (<year>2018</year>) <volume>2</volume>:<page-range>185&#8211;97</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/immunohorizons.1700063</pub-id><pub-id pub-id-type="pmid">31022686</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwak</surname><given-names>HW</given-names></name><name name-style="western"><surname>Park</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Ko</surname><given-names>HL</given-names></name><name name-style="western"><surname>Park</surname><given-names>H</given-names></name><name name-style="western"><surname>Cha</surname><given-names>MH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S-M</given-names></name><etal/></person-group><article-title>Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response</article-title>. <source>Vaccine</source> (<year>2019</year>) <volume>37</volume>:<page-range>5191&#8211;202</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.07.070</pub-id><pub-id pub-id-type="pmcid">PMC7115557</pub-id><pub-id pub-id-type="pmid">31371226</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>LC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Yao</surname><given-names>BY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JC</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus</article-title>. <source>Adv Funct Mater</source> (<year>2019</year>) <volume>29</volume>:<elocation-id>1807616</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1002/adfm.201807616</pub-id><pub-id pub-id-type="pmid">32313544</pub-id><pub-id pub-id-type="pmcid">PMC7161765</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#8217;kovski</surname><given-names>P</given-names></name><name name-style="western"><surname>Gultom</surname><given-names>M</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>S</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>J</given-names></name><name name-style="western"><surname>Russeil</surname><given-names>J</given-names></name><name name-style="western"><surname>Mangeat</surname><given-names>B</given-names></name><etal/></person-group><article-title>Disparate temperature-dependent virus-host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium</article-title>. <source>BioRxiv</source> (<year>2020</year>). &#160;<pub-id pub-id-type="doi">10.1101/2020.04.27.062315</pub-id><pub-id pub-id-type="pmcid">PMC8032198</pub-id><pub-id pub-id-type="pmid">33780434</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uematsu</surname><given-names>S</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Jang</surname><given-names>MH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>BG</given-names></name><name name-style="western"><surname>Jung</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>M</given-names></name><etal/></person-group><article-title>Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5</article-title>. <source>Nat Immunol</source> (<year>2008</year>) <volume>9</volume>:<page-range>769&#8211;76</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/ni.1622</pub-id><pub-id pub-id-type="pmid">18516037</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhun</surname><given-names>AS</given-names></name><name name-style="western"><surname>Haaheim</surname><given-names>LR</given-names></name><name name-style="western"><surname>Nostbakken</surname><given-names>JK</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T</given-names></name><name name-style="western"><surname>Chichester</surname><given-names>J</given-names></name><name name-style="western"><surname>Yusibov</surname><given-names>V</given-names></name><etal/></person-group><article-title>Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>4973&#8211;82</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.094</pub-id><pub-id pub-id-type="pmid">21600260</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity</article-title>. <source>Science</source> (<year>2020</year>) <volume>367</volume>:<fpage>869</fpage>. &#160;<pub-id pub-id-type="doi">10.1126/science.aau0810</pub-id><pub-id pub-id-type="pmcid">PMC7432993</pub-id><pub-id pub-id-type="pmid">32079747</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wan</surname><given-names>T</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><etal/></person-group><article-title>Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination</article-title>. <source>Nat Mater</source> (<year>2018</year>) <volume>17</volume>:<page-range>187&#8211;94</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nmat5057</pub-id><pub-id pub-id-type="pmid">29300052</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>X</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>AS</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></name><name name-style="western"><surname>Peng</surname><given-names>BH</given-names></name><name name-style="western"><surname>Wakamiya</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease</article-title>. <source>J Virol</source> (<year>2016</year>) <volume>90</volume>:<fpage>57</fpage>&#8211;<lpage>67</lpage>. &#160;<pub-id pub-id-type="doi">10.1128/JVI.02009-15</pub-id><pub-id pub-id-type="pmid">26446606</pub-id><pub-id pub-id-type="pmcid">PMC4702581</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection</article-title>. <source>Hum Vaccin Immunother</source> (<year>2017</year>) <volume>13</volume>:<page-range>1615&#8211;24</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2017.1296994</pub-id><pub-id pub-id-type="pmcid">PMC5512770</pub-id><pub-id pub-id-type="pmid">28277821</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X</given-names></name><etal/></person-group><article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection</article-title>. <source>Virology</source> (<year>2016</year>) <volume>499</volume>:<page-range>375&#8211;82</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.virol.2016.10.005</pub-id><pub-id pub-id-type="pmcid">PMC5167628</pub-id><pub-id pub-id-type="pmid">27750111</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>S</given-names></name><name name-style="western"><surname>Cao</surname><given-names>F</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>XD</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant</article-title>. <source>Adv Mater</source> (<year>2020</year>) <volume>32</volume>:<fpage>2004210</fpage>. &#160;<pub-id pub-id-type="doi">10.1002/adma.202004210</pub-id><pub-id pub-id-type="pmid">32864794</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>ME</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name><name name-style="western"><surname>Curti</surname><given-names>E</given-names></name><etal/></person-group><article-title>Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome</article-title>. <source>Expert Rev Vaccines</source> (<year>2012</year>) <volume>11</volume>:<page-range>1405&#8211;13</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/erv.12.126</pub-id><pub-id pub-id-type="pmcid">PMC3586247</pub-id><pub-id pub-id-type="pmid">23252385</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liao</surname><given-names>YP</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ku</surname><given-names>J</given-names></name><etal/></person-group><article-title>Enhanced Immune Adjuvant Activity of Aluminum Oxyhydroxide Nanorods through Cationic Surface Functionalization</article-title>. <source>ACS Appl Mater Interfaces</source> (<year>2017</year>) <volume>9</volume>:<page-range>21697&#8211;705</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acsami.7b05817</pub-id><pub-id pub-id-type="pmid">28590715</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Aldayel</surname><given-names>AM</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name></person-group><article-title>Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles</article-title>. <source>J Controlled Release</source> (<year>2014</year>) <volume>173</volume>:<page-range>148&#8211;57</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.jconrel.2013.10.032</pub-id><pub-id pub-id-type="pmcid">PMC3918952</pub-id><pub-id pub-id-type="pmid">24188959</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>